Clinical Trials Browser

Has results × simtuzumab × Gastrointestinal × Clear all

NCT01479465 2019-04-17

Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma

Phase 2 Terminated

266 enrolled 15 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms